BB Biotech Ag Approves Dividend, Payable on March 25, 2020; Announces Board Changes
March 19, 2020 at 04:40 pm
Share
BB Biotech AG approved dividend of CHF 3.40 per share, at its AGM held on March 19, 2020. Payment will be made on March 25, 2020, the record date is March 24, 2020 and the ex-dividend date is March 23, 2020.
The company also announced that Prof. Dr. Dr. Klaus Strein announced last year that he was stepping down from the Board and there did not stand for re-election. The Board of Directors thanks Klaus Strein for his valuable contribution and personal commitment to BB Biotech over the past seven years
The company also announced that two new directors were elected - Prof. Dr. Mads Krogsgaard Thomsen and, with effect from October 1, 2020, Dr. Susan Galbraith. Susan Galbraith joined AstraZeneca in 2010 and heads its Oncology Research and Early Development Department. She oversaw the successful development of several cancer drugs that have been approved worldwide. Mads Krogsgaard currently serves as Executive Vice President and Chief Science Officer with responsibility for global drug and device research, CMC and global drug development, regulatory affairs and drug safety.
BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Companyâs portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.